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Peripheral blood monocyte derived
dendritic cellsAllergic contact dermatitis is a delayed T-cell mediated allergic response associated with relevant social
and economic impacts. Animal experiments (e.g. the local lymph node assay) are still supplying most of
the data used to assess the sensitization potential of new chemicals. However, the 7th amendment to the
EU Cosmetic Directive have introduced a testing ban for cosmetic ingredients after March 2013.
We have developed and optimized a stable and reproducible in vitro protocol based on human periph-
eral blood monocyte derived dendritic cells to assess the sensitization potential of chemicals. To evaluate
the transferability and the predictivity of this PBMDCs based test protocol, a ring study was organized
with ﬁve laboratories using seven chemicals with a known sensitization potential (one none-sensitizer
and six sensitizers, including one pro-hapten).
The results indicated that this optimized test protocol could be successfully transferred to all partici-
pating laboratories and allowed a correct assessment of the sensitization potential of the tested set of
chemicals. This should allow a wider acceptance of PBMDCs as a reliable test system for the detection
of human skin sensitizers and the inclusion of this protocol in the toolbox of in vitromethods for the eval-
uation of the skin sensitization potential of chemicals.
 2015 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Allergic contact dermatitis (ACD) is a type-IV allergy of the skin
associated with signiﬁcant social and economic impact. The evalu-
ation of the skin sensitization potential of chemicals is thus a crucial
parameter in toxicological evaluation of chemicals that is usually
performed using animal models (e.g. the Local Lymph Node Assay
(LLNA) (Basketter et al., 2002)). However, the 7th Amendment to
the European Cosmetics Directive (Directive 76/768/EEC) severely
restricts the use of animal tests.
Different in vitro test protocols have thus been developed and
optimized for the detection of skin sensitizers (see for example(Aeby et al., 2010; Mehling et al., 2012). Most of them use cell
lines and measure similar dendritic cell (DC) activation markers.
For example, the h-CLAT protocol measures the expression of
CD86 and CD54 on THP-1 cells (Sakaguchi et al., 2006); the
MUSST assay evaluate the expression of CD86 on U937 cells
(Aeby et al., 2010). However, due to the difﬁculties associated
with cell lines such as altered genome, genomic instability, meta-
bolic deﬁciencies or limited functional properties (See for exam-
ple (Klein et al., 2006; Sabatier et al., 2005), we decided to
further evaluate a stable and reproducible in vitro protocol based
on human peripheral blood monocyte derived dendritic cells
(PBMDCs) that may provide additional and complementary infor-
mation to cell line based assays.
We have thus reinvestigated and optimized an in vitro approach
based on PBMDCs ((Aeby et al., 2004; Degwert et al., 1997; Reutter
H. Reuter et al. / Toxicology in Vitro 29 (2015) 976–986 977et al., 1997; Staquet et al., 2004) and established an improved and
stable protocol resulting in reduced donor to donor variability,
reproducible results and a signiﬁcant correlation with the local
lymph node assay (LLNA). This test method is based on human
PBMDCs and ﬂow cytometric measurement of CD86 expression
as an activation marker (Reuter et al., 2011). Moreover, a slightly
modiﬁed version of this protocol has already been shown to be
successful in identifying photosensitizers in vitro (Karschuk et al.,
2010).
The intra-laboratory performance of this test protocol was con-
sidered as very promising. However its transferability and reliabil-
ity had to be conﬁrmed. Thus a comprehensive ring study was
organized including ﬁve laboratories. A test set of seven chemicals
was ﬁrst deﬁned according to the following criterion: weak to
extreme sensitizers, including pre and pro-hapten and challenging
chemicals such as sodium lauryl sulfate (considered as a false pos-
itive in the LLNA, see for example (Garcia et al., 2010).
Each participating laboratory tested the same set of chemicals
using a variety of laboratory equipments and different adaptations
of the test protocols (fresh or ﬁxed cells, see below).
In this paper, we describe the setup, the performance of this
ring study and present and discuss the obtained results.2. Material and methods
2.1. Participating laboratories
Lead laboratory:
Beiersdorf AG, Research and Development, Unnastrasse 48, D-
20245 Hamburg, Germany (BDF).
Participating laboratories:
– BASF Product Safety – Experimental Toxicology and Ecology,
BASF SE, GV/TB – Z570, D-67056 Ludwigshafen, Germany
(BASF; Lab 1).
– Institut de Recherche Pïerre Fabre, Centre Expérimental et
Pharmacocinétique de Campans, Bel Air – Route de Lautrec,
F-81106 Castres cedex (PF; Lab 4).
– Johnson & Johnson GmbH, Johnson & Johnson Platz 2, D-41470
Neuss, Germany (J&J; Lab 2).Table 1
List, characteristics and test concentrations of the chemicals included in the ring study te
Name Abbreviation LLNA classiﬁcation CAS numb
Eugenol EUG Weak (pro-hapten) 97-53-0
Hydroxycitronellal HCIT Weak 107-75-5
Alpha-Hexylcinnamaldehyde HCA Moderate 101-86-0
Nickel sulfate NiSO4 Moderate 10101-97-
2,4-Dinitrochlorobenzene DNCB Extreme 97-00-7
Sodium lauryl sulfate SDS * 151-21-3
4-Hydroxybenzoic Acid HA Non sensitizer 99-96-7
* Non sensitizer in human, considered false positive in the LLNA and many cell based
§ Labs 1, 3 and 4 used 700 lM instead of 725 lM.– The Procter & Gamble Company, Mason Business Center, 8700
Mason Montgomery Road, Mason, Ohio 45040, USA (P&G;
lab 3).
2.2. Chemicals
The test chemicals were dissolved either in dimethylsulfoxide
(DMSO, Merck 1.029.50) or RPMI 1640 medium without phenol
red (R7509, Sigma, Germany, or USA). The desired test concentra-
tions were then obtained by diluting the solubilized chemicals in
RPMI 1640. When DMSO was used, its ﬁnal in-well concentration
of DMSO was always 0.5%. LPS (L5014, Sigma, USA) was included
in each test run as a functional control. Cytotoxicity was measured
by the incorporation of 7-aminoactinomycin D (7-AAD, 559925, BD
Biosciences, USA).
The chemicals included in the ring study test set are indicated
in Table 1. They were ordered independently by each participating
laboratory and were not blindly tested.2.3. Antibodies
All antibodies were obtained from BD Biosciences, San Jose, CA
95131, USA.
PE Mouse Anti-Human CD86: Cat. Nr. 555658.
PE Mouse Anti-Human CD1a: Cat. Nr. 555807.
FITC Mouse Anti-Human CD14: Cat. Nr. 345784.
Non-speciﬁc staining was determined using the following rele-
vant isotypic controls in parallel:
PE-Mouse IgG1: Cat. Nr. 349043.
FITC-Mouse IgG2a: Cat. Nr. 349051.2.4. Culture medium
Cells were cultured in RPMI 1640 without phenol red (R7509,
Sigma, Germany, or USA) supplemented with 10% fetal calf serum
(FCS Gold, A15-151, PAA, Austria or FCS Gold USA origin, A15-251,
PAA, Austria, respectively), previously heat inactivated for 30 min
at 56 C and 2 mM L-glutamine, 100 IU/ml penicillin, 100 lg/ml
streptomycin (P11-013, PAA, Austria; or G1146, Sigma, USA).st set.
er Source Purity Test concentrations (lM)
Aldrich
Cat. Nr. E51791
Lot BCBB3186
99% 50, 200, 350, 500, 650, 800, 950, 1100
BASF
Cat. Nr. 50001174
Lot 874256PO
P96% 350, 425, 500, 575, 650, 725§
SAFC
Cat. Nr. W256900
Lot 22297EJ010
95% 50, 60, 70, 80, 90, 100
0 Sigma
Cat. Nr. 039K0127
Lot 039K0127
99.9% 50, 100, 150, 200, 250, 300
Sigma
Cat. Nr. 237329
Lot 237329
P99% 2.5, 5.0, 7.5, 10.0, 12.5, 15.0
Merck
Cat. Nr. 112533
Lot L58114533 004
P99% 100, 200, 300, 400, 500, 600
Aldrich
Cat. Nr. 240141
Lot S79620-010
P99% 5000, 6000, 7000, 8000, 9000, 10000
in vitro assays.
Table 2
Classiﬁcation obtained in the ﬁve different laboratories: +: Sensitizer; : Non
sensitizer; +/: Equivocal; The detailed results are presented in Figs. 1–7.
SDS HA EUG HCIT HCA NiSO4 DNCB
Lab BDF +/  +/ + + + +
Lab 1 +/  + + + + +
Lab 2   + + + + +
Lab 3 +  + +  + +
Lab 4   + + Doubtful* + +
* Relevant increases in CD86 expression (>20%) were observed in 8 out of 9
donors.
978 H. Reuter et al. / Toxicology in Vitro 29 (2015) 976–9862.5. Puriﬁcation of human monocytes and differentiation into PBMDCs
PBMDCs were prepared as described (Reuter et al., 2011).
Brieﬂy, fresh buffy coats prepared by centrifugation were ran-
domly and anonymously obtained as residual product from whole
blood preservation production. Enriched mononuclear cells were
obtained by gradient density centrifugation (Lymphocyte
Separation Medium LSM 1077, J15-004, PAA, Austria or USA,
15 min at 800g, 20 C) as previously described (Degwert et al.,
1997). Alternatively, Leucosep separation tubes (Leucosep-Tubes,
227290 Greiner Bio One, Germany) can be used according to the
manufacturer’s instructions as an alternative to facilitate the sepa-
ration. CD14+ monocytes were then isolated by a positive selection
using anti-CD14-Ig coupled magnetic microbeads (MACS CD14
MicroBeads, human (130-050-201); Miltenyi Biotec, Germany or
USA). The isolated monocytes were frozen (1  1.5  107 cells/ml
in RPMI cryo medium (80% RPMI-medium + 10% DMSO + 10% FCS
heat inactivated) and stored at 80 C for a maximum period of
three months. Before differentiation to PBMDCs, cells were thawed,
resuspended in RPMI medium with cytokines (10% FCS (heat inac-
tivated 30 min at 56 C), 2 mM L-glutamine, 100 U/ml penicillin,
100 lg/ml streptomycin, 100 U/ml rh IL-4 (CS-C1064,
Cellsystems, Germany) and 200 U/ml recombinant human GM-
CSF (CS-C1038, Cellsystems, Germany)), and their CD14 phenotype
was measured by ﬂow cytometry.
The following acceptance criteria were deﬁned: Only cell sam-
ples containing > 70% CD14+ cells were used to generate PBMDCs
by incubating the cells (1  106/ml) from each donor in the RPMI
medium with cytokines (see above) for ﬁve days (37 C, 5%CO2)
in six well culture plates.A B
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Fig. 1. Results obtained with PBMDC exposed fo3. Experimental procedure
3.1. Dose selection process
As a ﬁrst step, the cytotoxicity of the chemicals included in the
test set was evaluated by the lead laboratory within a large con-
centration range limited only by their solubility. Brieﬂy, PBMDCs
were exposed for 48 h to the test chemical at dose-range concen-
trations, and the cytotoxicity was measured against an untreated
control: the concentration inducing 20% cytotoxicity or a 20%
induction of CD86 was ﬁrst determined by staining with 7-AAD
(BD559925; BD Biosciences, Basel, Switzerland) incorporation to
determine dead cells or CD86-FITC antibody respectively (Reuter
et al., 2011; Schmid et al., 1992), and ﬂow cytometry analysis
was performed. The ﬁnal test range (ﬁve concentrations) was then
deﬁned by choosing a minimum of four lower and one higher test
concentrations and communicated to the participating laboratories
(see Table 1).C
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concentration range and then analyzed by ﬂow cytometry for CD86
expression according to the protocol described below.3.2. Chemical treatment of PBMDCs
After thawing and ﬁve days in culture in six-well plates, the
cells were harvested and seeded in 24-well plates (7.5  105
cells/ml; 0.4 ml per well). The PBMDCs were then exposed for
48 h (37 C; 5% CO2) to the test chemicals (0.4 ml) at the 5 chosen
concentrations and (in an additional well) to 100 ng/ml of LPS as a
functional control (Reuter et al., 2011).
At the end of the exposure period, the cells were collected and
prepared for ﬂow cytometry analysis: 5  105 cells were trans-
ferred into fresh Eppendorf reaction tubes and centrifuged for
10 s at 1.3  103g. The supernatant was withdrawn and the cell
pellet resuspended in 100 ll FACS-buffer (PBS (without Ca2+ and
Mg2+) containing 0.05% sodium azide). 15 ll of the antibody solu-
tion (test antibody or isotype control) were added and cells were
incubated for 25 min at 4 C in the dark. The cells were then
washed with 500 ll of FACS-buffer (centrifugation) and resus-
pended in 500 ll of FACS-buffer for analysis.
For viability measurement, the antibody stained cells were pel-
leted and resuspended in 100 ll FACS-buffer before addition of
2.5 ll (0.125 lg) 7-AAD. The cells were then incubated for
10 min at 4 C and 400 ll FACS-buffer added before analysis.
Alternatively, to facilitate the work of laboratories without
onsite ﬂow cytometry facility, control cells (for monitoring the
CD14 phenotype at day 0 or CD1a phenotype at day 5) were ﬁxed
in PBS with 1% para-formaldehyde and 0.05% sodium azide (freshly
prepared or thawed) and analyzed later.A B
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Fig. 2. Results obtained with PBMDC exposed fo3.3. Flow cytometry analysis
The ﬂow cytometry analysis of the cell viability (7-AAD incor-
poration) and CD86 surface expression was performed as already
described (Reuter et al., 2011): Brieﬂy, 104 cells were analyzed
and gates for lymphocytes and debris exclusion were set based
on forward and sideward scatter signals. Dead cells were assessed
based on 7-AAD signals (Schmid et al., 1992) and excluded from
the CD86 analysis. The isotype control was set to 1%. The percent-
age of cells positive for the analyzed marker (e.g. CD86) was
deﬁned as the% cells showing a signal above the 1% threshold set
with the isotype control.
3.4. Data analysis
Each chemical was tested in at least ﬁve independent experi-
ments corresponding to 5 different donors and for each test con-
centration the mean of the results obtained with the 5 donors
was calculated. CD1a analysis was performed on the negative con-
trol only and CD86 and 7-AAD values were determined for all sam-
ples. For each experiment, the following acceptance criteria were
set for the negative control: CD86 positive cells < 60%, CD1a posi-
tive cells > 60% and 7-AAD positive cells < 8.5%. Experiments not
fulﬁlling these criteria were discarded.
The induction of CD86 expression after treatment was calcu-
lated as the difference to untreated controls (DCD86 = % CD86+
cells in substance treated sample – % CD86+ cells in untreated
sample).
If a DCD86 > 20% was obtained for any concentration within the
acceptable cytotoxicity range (cytotoxicity < 20%, see above), it
was considered as a relevant increase and classiﬁed the substance
as a sensitizer. However, if only one concentration reach theC
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980 H. Reuter et al. / Toxicology in Vitro 29 (2015) 976–986DCD86 > 20% threshold before the cytotoxicity range, the result is
considered as equivocal (+/).
The extrapolated concentration inducing a DCD86  20% (inter-
section of the 20% threshold) was calculated through a linear
regression between the ﬁrst concentration inducing the
DCD86 > 20% and the one just below (mean of 5 donors).3.5. Statistical analysis
Descriptive and inductive statistics were performed on the
inter-laboratory data according to the method two-way ANOVA
with interaction using the SAS statistical computing package for
Windows V9.2 (www.sas.com).
The inductive statistic results presented in Table 3b has been
obtained using the following parameters: Two sided hypothesis
test and a 0.05 signiﬁcance level. Moreover, for multiple com-
parisons, two types of signiﬁcance were computed: ‘‘signiﬁcant
on multiple levels’’ (a multiple level of 0.05 was used) and ‘‘sig-
niﬁcant at the local level’’ (a local level of 0.05 was also used).
Both types of signiﬁcance are considered relevant to the claim
support. Compliance with the multiple levels ensures a higher
reproducibility of the signiﬁcances obtained in this study.
An analysis of variance with laboratory and substance as the
main effects and an interaction between laboratory and substance
was calculated. The main effects describe the global differences
between the laboratories. The interaction describes the differences
between the laboratories per substance.A B
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Fig. 3. Results obtained with PBMDC exposed fo4. Results
4.1. The test protocol was successfully transferred to all participating
laboratories
Each participating laboratory was ﬁrst trained in the lead labo-
ratory facility.
Transferability was ﬁrst assessed by the lead laboratory through
a functional test with LPS and the correct classiﬁcation of HA (neg-
ative) and DNCB (positive) by all participating laboratories (Data
not shown).
At the beginning the ring study, all laboratories experienced a
similar high rate (up to 30%) of experiment rejection (see accep-
tance criteria under Data analysis). This was mainly due to the
use of >24 h old buffy coats. This rejection rate was reduced
>10% in subsequent experiments through the use of fresher
(<24 h) buffy coats and additional hands-on experience with the
DC isolation procedure.
4.2. Results obtained with the chemical test set
Each participating laboratory evaluated the chemical test set at
the predetermined concentrations (Table 1) according to the
shared protocol (see above). Experiments not fulﬁlling the
described acceptance criteria (negative control values:
CD86 < 60%, CD1a > 60% and 7-AAD < 8.5%) were rejected and not
included in the ﬁnal evaluation. The induction of CD86 expression
after treatment was measured and the corresponding DCD86
calculated.C
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was >20% within the acceptable cytotoxicity range. The overall
results are summarized in Table 2.
SDS: (non-sensitizer, irritant; Fig. 1): In all laboratories SDS
induced a >20% increase in CD86 expression at concentrations
ranging from 289 lM to 362 lM with a median of 297 lM (values
obtained by linear regression intersection of the 20% threshold).
However, in Labs 2 and 4, >20% increases in CD86 expression were
only observed at cytotoxic concentrations (>20% cytotoxicity) and
were thus considered as non-relevant, negative results. In the lead
Lab and in Lab 1, the results were considered as equivocal since
weak increases (EC20: 289 lM and 290 lM) were only observed
at one concentration (300 lM) before inducing cytotoxic effects.
HA: (non-sensitizer; Fig. 2): In all laboratories, HA did not
induce any cytotoxicity (cytotoxicity < 20%) or increase in CD86
expression (DCD86 < 20%) up to the highest tested concentration
(10,000 lM). No dose effect was observed. Due to the absence of
CD86 induction up to the highest tested concentrations, HA was
classiﬁed as a non-sensitizer by all laboratories.
EUG: (Weak sensitizer, pro-hapten; Fig. 3): The lead lab and
labs 1, 2 and 4 observed cytotoxic effects at test concentrations
ranging from 650 to 1100 lM (Linear regression intersection of
the 20% threshold at 567 lM to over 1100 lM). In Lab 3, EUG did
not induce any cytotoxicity (above the set thresholds) up to the
highest tested concentration (1100 lM). In all laboratories EUG
induced increases in CD86 expression (DCD86 > 20%) at concentra-
tions ranging from 137 lM to 371 lM with a median at 222 lM
(linear regression intersection of the 20% threshold). Due to the
induction of increases of CD86 expression at non-cytotoxic concen-
trations, labs 1–4 classiﬁed EUG as a sensitizer. In the lead lab EUGA B
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Fig. 4. Results obtained with PBMDC exposed foinduced a DCD86 > 20% at only one concentration before the cyto-
toxicity range and was thus classiﬁed as equivocal (+/).
HCIT: (Weak sensitizer; Fig. 4): In all laboratories HCIT induced
DCD86 > 20% at concentrations ranging from 431 lM to 643 lM
with a median of 505 lM (values obtained by linear regression
intersection of the 20% threshold). Due to the induction of these
CD86 expression at non-cytotoxic concentrations, all laboratories
classiﬁed HCIT as a sensitizer.
HCA: (Moderate sensitizer (LLNA); Fig. 5): All laboratories but
one (Lab 3) observed cytotoxic effects at test concentrations > 80
(lab 1) or at 100 lM. In Lab 3, HCA did not induce any cytotoxic-
ity > 20% up to the highest tested concentration (100 lM). All lab-
oratories but one (Lab 3) observed DCD86 > 20% at concentrations
ranging from 51 lM to 77 lM with a median of 55 lM (values
obtained by linear regression intersection of the 20% threshold).
However, Lab 4 also observed dose related increases in CD86
expression at concentrations up to 90 lM but the mean increases
did not reach the 20% threshold. Nevertheless, DCD86 > 20% were
observed in 8 out of 9 donors but the mean value obtained for
the 9 donors did not reach the pre-deﬁned 20% threshold. This
result was thus considered has doubtful. In Lab3, increases in the
expression of the CD86 marker were observed at the 60–100 lM
test concentrations. However, these increases did not reach the
20% threshold and Lab 3 classiﬁed HCA as a non-sensitizer.
NiSO4: (Moderate sensitizer; Fig. 6): Within the chosen test
range, a >20% (but weak) cytotoxic effect was only observed in lab-
oratory 4, at the highest test concentration (300 lM; linear regres-
sion intersection of the 20% threshold at 279 lM). Nevertheless, in
all laboratories NiSO4 induced DCD86 > 20% at concentrations
ranging from 54 lM to 196 lM with a median of 75 lM (valuesC
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982 H. Reuter et al. / Toxicology in Vitro 29 (2015) 976–986obtained by linear regression intersection of the 20% threshold).
Due to the induction of these increases of CD86 expression at
non-cytotoxic concentrations, all laboratories classiﬁed NiSO4 as
a sensitizer.
DNCB: (Extreme sensitizer; Fig. 7): The selected test concentra-
tions for this highly cytotoxic compound were comparatively low
(2.5–15.0 lM). According to the linear regression intersection of
the 20% threshold, cytotoxicity was observed by the lead Lab and
Labs 1 and 4 at concentrations higher than 11.1 lM. Cytotoxicity
values obtained in Lab 2 and 3 did not reach the 20% threshold.
With DNCB, all laboratories observed increases in CD86 expression
over the 20% threshold (linear regression intersection of the 20%
threshold) at test concentrations ranging from 3.8 and 8.7 lM
(median 7 lM). DNCB was thus classiﬁed as a sensitizer by all lab-
oratories. These results also conﬁrmed the successful transfer of
the test protocol in all participating laboratories.4.3. Statistical analysis
The descriptive statistical results are summarized in Fig. 8. The
CV80 (test concentration inducing 20% cytotoxicity, e.g. viabil-
ity < 80%) and EC20 (test concentration inducing a >20% increase
in CD86 expression) values for the different substances in different
study laboratories are summarized. Inductive statistical results are
summarized in Table 3a. The computed values indicate that the
hypothesis of relevant differences between substances is true.
Moreover an inductive statistical comparison of the results
between laboratories and substances (see Supplementary
Table S1) indicates that there was no statistically signiﬁcant differ-
ence between the results obtained by the laboratories with allA B
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Fig. 5. Results obtained with PBMDC exposed fotested chemicals except for one: NiSO4. However, this had no con-
sequence since all labs classiﬁed NiSO4 as a sensitizer! These
results conﬁrm the good inter-laboratory reproducibility of the
evaluated protocol. Table 3b presents the results of the inductive
comparison between laboratories. Again, no statistically relevant
difference could be observed between the results obtained in each
laboratory.5. Discussion
We have recently published an optimized test protocol using
PBMDCs for the in vitro detection of contact allergens (Reuter
et al., 2011). The choice of PBMDCs as the test system instead of
cell lines such as THP-1 or U-937 (Ade et al., 2006; Ashikaga
et al., 2006; Bauch et al., 2012; Python et al., 2007; Sakaguchi
et al., 2006) was based on the fact that PBMDCs are primary human
cells that are not degenerated through the aberrant expression of
oncogenes or modiﬁed signaling pathways and are thus physiolog-
ically and metabolically very similar to functional DCs. Through a
comprehensive review, evaluation and optimization of the already
published PBMDCs based protocols (Aeby et al., 2004; Degwert
et al., 1997; Reuter et al., 2011; Reutter et al., 1997; Staquet
et al., 2004) a simple and robust approach was developed.
Preliminary evaluation of this optimized protocol by the lead lab-
oratory, BDF (Reuter et al., 2011), using a limited test set of chem-
icals demonstrated its excellent performance: A correct
classiﬁcation (7 sensitizers/5 non-sensitizers) was obtained for
all chemicals but one (benzalkonium chloride). However, a
detailed and meaningful statistical analysis of the within- or
between-laboratory reproducibility, robustness and speciﬁcityC
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laboratory ring study.
In this paper, we present the results of such a ring study per-
formed with ﬁve participating laboratories with quite diverse
previous expertise concerning the isolation and culture of human
monocytes and using a variety of equipments. As a starting point,
a test set of seven chemicals was ﬁrst deﬁned according to the
following criterion: Weak to extreme sensitizers, including pro-
haptens and a metal and non-sensitizers (irritant and non-irri-
tant). The test set (see Table 1) deﬁned according to these crite-
rion was: eugenol as a weak pro-hapten, hydroxycitronellal and
alpha-hexylcinnamaldehyde as weak or moderate direct acting
sensitizers, nickel sulfate as a moderate, metal sensitizer and
2,4-dinitrochlorobenzene as an extreme sensitizer (Gerberick
et al., 2004; Kimber et al., 2003; Loveless et al., 1996). The
selected non-sensitizers were sodium lauryl sulfate (irritant,
non sensitizer in human but considered false positive in the
LLNA (Basketter and Kimber, 2011) and many cell based
in vitro assays) and 4-hydroxybenzoic acid. Each participating
laboratory received and tested the same lot of each of the test
chemicals.
The primary goal of this ring study was to evaluate the transfer-
ability and to assess the reliability (speciﬁcity) of the proposed test
protocol in different laboratory environments. Indeed, this opti-
mized protocol could be, after a short (3 days) learning phase orga-
nized within the lead laboratory (BDF), easily transferred to the
participating laboratories that all had a different background
regarding the technologies and procedures needed for the evalua-
tion of the proposed protocol:A B
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Fig. 6. Results obtained with PBMDC exposed forLab 1: The personnel involved in this study had limited previous
experience with ﬂow cytometry and was never involved in
PBMDCs isolation procedures such as density gradient centrifuga-
tion, and bead-based cell isolation.
Lab 2: The personnel had a limited prior experience with in vitro
cell culture but no previous practice with the isolation, culture and
activation of PBMDCs or ﬂow cytometry analysis. This facility
should thus be considered as a true naïve laboratory without pre-
vious experience with the evaluated PBMDC activation protocol.
Lab 3: The personnel had an extensive expertise in PBMDC iso-
lation, culture, activation as well as ﬂow cytometry analysis. They
were already involved in the development of alternative in vitro
methods.
Lab 4: The personnel had experience in cell culture procedures,
however with only a limited previous knowledge of PBMDC isola-
tion and culture and nearly no experience of ﬂow cytometry.
The successful transfer of the protocol to laboratories with such
different experiences and equipment indicates that this is an easily
deployable test protocol that was resilient to the inevitable labora-
tory adaptation. The fact that each participating laboratory could
successfully isolate it’s own biological material (PBMDC) further
stress the robustness of the protocol. The preliminary and encour-
aging observations made during the transfer phase were conﬁrmed
by the ring study results discussed below:
HA was correctly classiﬁed by all laboratories as a non-sensi-
tizer since it did not induce anyDCD86 > 20% up to the highest test
concentration (10,000 lM).
On the other hand, with SDS, different and sometimes border-
line results were obtained: two laboratories (Lab 2 & 4) categorizedC
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Fig. 7. Results obtained with PBMDC exposed for 48 h to the indicated DNCB concentrations.
Fig. 8. CV80 (test concentration inducing 20% cytotoxicity, e.g. viability < 80%) and EC20 (test concentration inducing a >20% increase in CD86 expression) values obtained for
the different substances in the indicated laboratories. X-axis: Test substance; Y-axis: Test substance concentration (in lM).
984 H. Reuter et al. / Toxicology in Vitro 29 (2015) 976–986SDS as a non-sensitizer, one laboratory (Lab 3) as a sensitizer and
the two others (Lead Lab and Lab 1) had equivocal results. All lab-
oratories observed DCD86 > 20% on cells exposed to SDS. However
in two laboratories, these increases were only observed outside the
acceptable cytotoxicity threshold (20%). SDS was classiﬁed as a non
sensitizer in these laboratories. In Lab 3, SDS induced a
DCD86 > 20% at 400 and 500 lM within the acceptable cytotoxic
range (<20% cytotoxicity) and was thus categorized a sensitizer.In Lab 1 and in the lead Lab, a borderline situation was observed:
SDS induced a weak increase in CD86 expression at only one con-
centration before inducing cytotoxic effects. These laboratories
thus categorized SDS as an equivocal sensitizer. However, the mea-
surement of the proportion of dead cells after exposure to surfac-
tants such as SDS is quite challenging since lysed cells will not
be detected by the ﬂow cytometer and the cytotoxic effects are
thus grossly under evaluated. Moreover, cell responses observed
H. Reuter et al. / Toxicology in Vitro 29 (2015) 976–986 985in the cytotoxic range can be due to various artifacts (e.g. danger
signals due to the release of cell components by dying or dead cells
or to cytokines released by stressed cells (Reuter et al., 2011) and
should thus not be considered for the categorization of a chemical.
SDS is a known human irritant classiﬁed as a non-sensitizer in
humans and as a false positive in the LLNA (Basketter and
Kimber, 2011). It has already proven to be a difﬁcult chemical
when tested in various in vitro approaches (Hooyberghs et al.,
2008; Python et al., 2007).
EUG is known as a weak sensitizer acting as a pro-hapten (e.g.
it needs to be metabolically converted into a compound that is
chemically reactive (Barratt and Basketter, 1992; Bertrand et al.,
1997; Jäckh et al., 2012). Laboratories 1–4 correctly categorized
this compound as a sensitizer since it induced DCD86 > 20% at
non-cytotoxic concentrations. The lead lab indicated an equivocal
result since EUG induced a relevant increase at only one concen-
tration before the cytotoxicity range. This successful detection of
a typical pro-hapten also supports our hypothesis that a test sys-
tem based on primary human cells has the potential to detect
chemicals classiﬁed as pro-haptens. This should be conﬁrmed
by testing more pro-haptens. Moreover, donor-to-donor-varia-
tions in detecting pro-haptens may arise from differences in
metabolic capacity.
HCIT is known as a direct acting, weak sensitizer (Gerberick
et al., 2004). As expected, it induced DCD86 > 20% at non-cytotoxic
concentrations and all laboratories correctly categorized it as a
sensitizer. Interestingly, within the tested range (350–725 lM)
HCIT did not induce reproducible cytotoxic effects (only Lab 1
detected a relevant (>20%) cytotoxic reaction at the highest tested
concentration (700 lM)). A clear DCD86 dose response was never-
theless observed indicating that the increase in CD86 expression is
not necessarily correlated with relevant cytotoxic effects.
HCA has been classiﬁed in the LLNA as moderate sensitizer
(Gerberick et al., 2004). In this ring study, three laboratories
observed DCD86 > 20% at non-cytotoxic concentrations and a
fourth one obtain a doubtful result since it observed relevant
increases in CD86 expression (>20%) in 8 out of 9 donors but the
mean value including this negative donor did not reach the pre-de-
ﬁned 20% threshold. HCA was thus classiﬁed as a sensitizer in three
laboratories and as a non-sensitizer by Lab 3. However, the nega-
tive classiﬁcation of Lab 3 could be due to the limited test concen-
tration range indicated by the lead laboratory. Under standard
experimental conditions, Lab 3 would have tested HCA at higher,Table 3
Inductive statistical results on the ring study.
(a)
EC20
Effect F-value Pr > F
Inductive statistics for the global model; F-value: test factor; Pr > F: p-value
Labor 2.0 0.0974
Substance 3.998E7 <.0001
(b)
Comparison Adjusted p-value Result
Inductive comparisons between laboratories across substances. n.s.: not
signiﬁcant
BASF  BDF 0.0593 n.s.
BASF  J&J 0.9198 n.s.
BASF  P&G 0.5496 n.s.
BASF  PF 0.4497 n.s.
BDF  J&J 0.3508 n.s.
BDF  P&G 0.7732 n.s.
BDF  PF 0.7852 n.s.
J&J  P&G 0.9597 n.s.
J&J  PF 0.9310 n.s.
P&G  PF 1.0000 n.s.up to sub-cytotoxic, concentrations as deﬁned in the test protocol
and may have observed a D CD86 > 20%. It is interesting to note
that a large variability in the response to HCA has already been
reported by other groups: In humans, only few positive HCA
patch-test reactions were reported by (Heydorn et al., 2003) indi-
cating that negative results may be expected when using a test sys-
tem based on cells of human origin. Negative results were also
observed by (Python et al., 2007) using the U937 cells that are also
of human origin. HCA also gave equivocal results in the COLIPA h-
CLAT ring trial (Sakaguchi et al., 2010).
On the other hand, NiSO4 is a well-known moderate human
sensitizer that generally tests negative in the LLNA. This discrep-
ancy has recently been elucidated and is due to binding to the
human TLR-4 receptor but not to the corresponding murine recep-
tor (Mandervelt et al., 1997; Schmidt et al., 2010). In this ring
study, it induced DCD86 > 20% at non-cytotoxic concentrations
and was thus clearly categorized as a sensitizer by all laboratories.
This result again emphasizes the advantage of using cells of human
origin for the detection of human allergens and fully agrees with
the current understanding of the species-speciﬁc Ni2+ -induced
TLR4 activation process.
DNCB has been categorized as an extreme sensitizer in the LLNA
(Gerberick et al., 2004). It is nevertheless a challenging compound
when tested in cell based in vitro assays due to its relatively high
cytotoxicity and the reduced concentration range (narrow test
window) where DC activation occurs before inducing unacceptable
cytotoxic effects. DNCB was nevertheless correctly classiﬁed as a
sensitizer in all the laboratories participating to the ring trial. It
is interesting to note that all laboratories observed increases in
CD86 expression over the 20% threshold at very low test concen-
trations (median 7 lM, calculated from a linear regression inter-
section of the 20% threshold), indicating the possibility of using
the intersection of the 20% threshold as an indicator of the potency
of test substance.6. Conclusion
This ring study exercise has conﬁrmed the transferability of this
optimized PBMDC protocol in laboratories with a wide range of
expertise regarding the isolation, culture and analysis of human
monocytes. Furthermore, its robustness was also demonstrated
by the concordant and correct results obtained using different ver-
sions of the protocol adapted to the available laboratory equip-
ment (e.g. four different ﬂow cytometry apparatus) and by the
successful use of a biological source material (buffy coats) obtained
from different populations originating from Germany, France and
the United States (Fig. 8).
Quality information to characterize the sensitizing properties of
a chemical will rely on the combination of multiple in vitro or in sil-
ico test methods. This test protocol using DC derived from fully
functional human primary cells as the test system does not suffer
from the inherent functional and metabolic limitations of cell line
based assays. It can thus provide additional and/or conﬁrmatory
information to other assays (e.g. DPRA, h-CLAT, MUSST) and be
included in a comprehensive test strategy (Goebel et al., 2012). A
successful double blinded study with a larger chemical test set
would support it’s validation and acceptability for inclusion in
the toolbox of in vitro methods for the evaluation of the skin sen-
sitization potential of chemicals, together with already validated
assays such as the DPRA and the h-CLAT.Conﬂict of Interest
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